nodes	percent_of_prediction	percent_of_DWPC	metapath
Afatinib—ERBB2—connective tissue—Graves' disease	0.0286	0.0737	CbGeAlD
Afatinib—PHKG2—adipose tissue—Graves' disease	0.0244	0.0628	CbGeAlD
Afatinib—ERBB4—pituitary gland—Graves' disease	0.0221	0.0567	CbGeAlD
Afatinib—ERBB2—adipose tissue—Graves' disease	0.022	0.0565	CbGeAlD
Afatinib—ERBB4—adipose tissue—Graves' disease	0.022	0.0565	CbGeAlD
Afatinib—PHKG2—thyroid gland—Graves' disease	0.0211	0.0544	CbGeAlD
Afatinib—DYRK1A—adipose tissue—Graves' disease	0.0211	0.0544	CbGeAlD
Afatinib—ERBB4—thyroid gland—Graves' disease	0.019	0.0489	CbGeAlD
Afatinib—ERBB2—thyroid gland—Graves' disease	0.019	0.0489	CbGeAlD
Afatinib—EGFR—adipose tissue—Graves' disease	0.0186	0.0479	CbGeAlD
Afatinib—DYRK1A—thyroid gland—Graves' disease	0.0183	0.0471	CbGeAlD
Afatinib—IRAK1—adipose tissue—Graves' disease	0.0164	0.0423	CbGeAlD
Afatinib—EGFR—thyroid gland—Graves' disease	0.0161	0.0415	CbGeAlD
Afatinib—LCK—adipose tissue—Graves' disease	0.016	0.0412	CbGeAlD
Afatinib—IRAK1—thyroid gland—Graves' disease	0.0142	0.0366	CbGeAlD
Afatinib—LCK—thyroid gland—Graves' disease	0.0139	0.0357	CbGeAlD
Afatinib—ABL1—eye—Graves' disease	0.0125	0.032	CbGeAlD
Afatinib—ABL1—connective tissue—Graves' disease	0.012	0.0309	CbGeAlD
Afatinib—ABL1—pituitary gland—Graves' disease	0.00924	0.0238	CbGeAlD
Afatinib—ABL1—adipose tissue—Graves' disease	0.0092	0.0237	CbGeAlD
Afatinib—ABL1—thyroid gland—Graves' disease	0.00797	0.0205	CbGeAlD
Afatinib—ABCG2—pituitary gland—Graves' disease	0.00583	0.015	CbGeAlD
Afatinib—ABCG2—adipose tissue—Graves' disease	0.0058	0.0149	CbGeAlD
Afatinib—ABCG2—thyroid gland—Graves' disease	0.00502	0.0129	CbGeAlD
Afatinib—Interstitial lung disease—Propylthiouracil—Graves' disease	0.00377	0.2	CcSEcCtD
Afatinib—ABCB1—pituitary gland—Graves' disease	0.00287	0.00739	CbGeAlD
Afatinib—ABCB1—adipose tissue—Graves' disease	0.00286	0.00736	CbGeAlD
Afatinib—ABCB1—thyroid gland—Graves' disease	0.00248	0.00637	CbGeAlD
Afatinib—Alopecia—Methimazole—Graves' disease	0.00139	0.0738	CcSEcCtD
Afatinib—Alopecia—Propylthiouracil—Graves' disease	0.00119	0.0627	CcSEcCtD
Afatinib—Dysgeusia—Propylthiouracil—Graves' disease	0.00114	0.0605	CcSEcCtD
Afatinib—EGFR—DAP12 interactions—HLA-B—Graves' disease	0.00109	0.00183	CbGpPWpGaD
Afatinib—ERBB2—Disease—B3GNT2—Graves' disease	0.00107	0.00181	CbGpPWpGaD
Afatinib—BLK—Adaptive Immune System—CTLA4—Graves' disease	0.00107	0.00181	CbGpPWpGaD
Afatinib—EGFR—MAPK Signaling Pathway—FAS—Graves' disease	0.00107	0.0018	CbGpPWpGaD
Afatinib—ABCG2—Transmembrane transport of small molecules—GABRA3—Graves' disease	0.00106	0.0018	CbGpPWpGaD
Afatinib—ERBB4—Disease—B3GNT2—Graves' disease	0.00106	0.00179	CbGpPWpGaD
Afatinib—IRAK1—Cytokine Signaling in Immune system—IL2RA—Graves' disease	0.00105	0.00178	CbGpPWpGaD
Afatinib—LCK—DAP12 interactions—HLA-B—Graves' disease	0.00105	0.00177	CbGpPWpGaD
Afatinib—ABCB1—Allograft Rejection—HLA-B—Graves' disease	0.00104	0.00176	CbGpPWpGaD
Afatinib—IRAK1—Cytokine Signaling in Immune system—HLA-A—Graves' disease	0.00104	0.00176	CbGpPWpGaD
Afatinib—ABCB1—Allograft Rejection—FASLG—Graves' disease	0.00102	0.00172	CbGpPWpGaD
Afatinib—LCK—Cytokine Signaling in Immune system—HLA-E—Graves' disease	0.00102	0.00172	CbGpPWpGaD
Afatinib—IRAK1—Toll-like Receptor Signaling Pathway—TNF—Graves' disease	0.00101	0.0017	CbGpPWpGaD
Afatinib—EGFR—Integrated Pancreatic Cancer Pathway—FASLG—Graves' disease	0.000999	0.00169	CbGpPWpGaD
Afatinib—Dyspepsia—Methimazole—Graves' disease	0.000986	0.0522	CcSEcCtD
Afatinib—ABCB1—Allograft Rejection—FAS—Graves' disease	0.000985	0.00166	CbGpPWpGaD
Afatinib—ABCB1—Allograft Rejection—IL2RA—Graves' disease	0.000979	0.00165	CbGpPWpGaD
Afatinib—ABCB1—Allograft Rejection—HLA-A—Graves' disease	0.000968	0.00163	CbGpPWpGaD
Afatinib—EGFR—Integrated Pancreatic Cancer Pathway—FAS—Graves' disease	0.000963	0.00163	CbGpPWpGaD
Afatinib—IRAK1—Cytokine Signaling in Immune system—HLA-DRB1—Graves' disease	0.000952	0.00161	CbGpPWpGaD
Afatinib—ERBB2—Adaptive Immune System—HLA-DQB1—Graves' disease	0.000933	0.00157	CbGpPWpGaD
Afatinib—EGFR—Spinal Cord Injury—IFNG—Graves' disease	0.000928	0.00157	CbGpPWpGaD
Afatinib—ERBB4—Adaptive Immune System—HLA-DQB1—Graves' disease	0.000919	0.00155	CbGpPWpGaD
Afatinib—IRAK1—Cytokine Signaling in Immune system—ICAM1—Graves' disease	0.000914	0.00154	CbGpPWpGaD
Afatinib—ERBB2—Immune System—IFIH1—Graves' disease	0.000907	0.00153	CbGpPWpGaD
Afatinib—ERBB4—Immune System—IFIH1—Graves' disease	0.000893	0.00151	CbGpPWpGaD
Afatinib—Body temperature increased—Methimazole—Graves' disease	0.000886	0.0469	CcSEcCtD
Afatinib—IRAK1—Innate Immune System—HLA-E—Graves' disease	0.000885	0.00149	CbGpPWpGaD
Afatinib—ABCB1—Allograft Rejection—HLA-DRB1—Graves' disease	0.000885	0.00149	CbGpPWpGaD
Afatinib—BLK—Adaptive Immune System—HLA-DQB1—Graves' disease	0.000884	0.00149	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—IFIH1—Graves' disease	0.000881	0.00149	CbGpPWpGaD
Afatinib—PHKG2—Disease—HLA-A—Graves' disease	0.000877	0.00148	CbGpPWpGaD
Afatinib—ERBB2—Innate Immune System—HLA-B—Graves' disease	0.000873	0.00147	CbGpPWpGaD
Afatinib—ERBB2—Adaptive Immune System—CD8A—Graves' disease	0.000871	0.00147	CbGpPWpGaD
Afatinib—ERBB4—Innate Immune System—HLA-B—Graves' disease	0.00086	0.00145	CbGpPWpGaD
Afatinib—BLK—Immune System—IFIH1—Graves' disease	0.000859	0.00145	CbGpPWpGaD
Afatinib—ERBB4—Adaptive Immune System—CD8A—Graves' disease	0.000858	0.00145	CbGpPWpGaD
Afatinib—LCK—Signaling by Interleukins—IL1B—Graves' disease	0.000857	0.00145	CbGpPWpGaD
Afatinib—ERBB2—Integrated Pancreatic Cancer Pathway—TNF—Graves' disease	0.000846	0.00143	CbGpPWpGaD
Afatinib—Dyspepsia—Propylthiouracil—Graves' disease	0.000839	0.0444	CcSEcCtD
Afatinib—ERBB2—Adaptive Immune System—HLA-B—Graves' disease	0.000838	0.00141	CbGpPWpGaD
Afatinib—EGFR—Spinal Cord Injury—IL1B—Graves' disease	0.000828	0.0014	CbGpPWpGaD
Afatinib—LCK—HIV Infection—HLA-A—Graves' disease	0.000827	0.0014	CbGpPWpGaD
Afatinib—BLK—Adaptive Immune System—CD8A—Graves' disease	0.000825	0.00139	CbGpPWpGaD
Afatinib—ERBB4—Adaptive Immune System—HLA-B—Graves' disease	0.000825	0.00139	CbGpPWpGaD
Afatinib—LCK—Platelet activation, signaling and aggregation—IL2RA—Graves' disease	0.000821	0.00139	CbGpPWpGaD
Afatinib—LCK—Host Interactions of HIV factors—CD4—Graves' disease	0.00082	0.00138	CbGpPWpGaD
Afatinib—LCK—Cytokine Signaling in Immune system—HLA-DQB1—Graves' disease	0.000807	0.00136	CbGpPWpGaD
Afatinib—BLK—Adaptive Immune System—HLA-B—Graves' disease	0.000794	0.00134	CbGpPWpGaD
Afatinib—Pruritus—Methimazole—Graves' disease	0.000793	0.042	CcSEcCtD
Afatinib—IRAK1—Regulation of toll-like receptor signaling pathway—TNF—Graves' disease	0.000788	0.00133	CbGpPWpGaD
Afatinib—ERBB2—Adaptive Immune System—HLA-A—Graves' disease	0.000776	0.00131	CbGpPWpGaD
Afatinib—ERBB4—Adaptive Immune System—HLA-A—Graves' disease	0.000765	0.00129	CbGpPWpGaD
Afatinib—Body temperature increased—Propylthiouracil—Graves' disease	0.000753	0.0399	CcSEcCtD
Afatinib—EGFR—Innate Immune System—IFIH1—Graves' disease	0.000753	0.00127	CbGpPWpGaD
Afatinib—BLK—Adaptive Immune System—HLA-A—Graves' disease	0.000736	0.00124	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—IFIH1—Graves' disease	0.000725	0.00122	CbGpPWpGaD
Afatinib—LCK—Cytokine Signaling in Immune system—HLA-B—Graves' disease	0.000725	0.00122	CbGpPWpGaD
Afatinib—ERBB2—Immune System—HLA-E—Graves' disease	0.000713	0.0012	CbGpPWpGaD
Afatinib—Vomiting—Methimazole—Graves' disease	0.000713	0.0377	CcSEcCtD
Afatinib—ERBB2—Adaptive Immune System—HLA-DRB1—Graves' disease	0.000709	0.0012	CbGpPWpGaD
Afatinib—Rash—Methimazole—Graves' disease	0.000707	0.0374	CcSEcCtD
Afatinib—Dermatitis—Methimazole—Graves' disease	0.000706	0.0374	CcSEcCtD
Afatinib—ERBB4—Immune System—HLA-E—Graves' disease	0.000703	0.00119	CbGpPWpGaD
Afatinib—Headache—Methimazole—Graves' disease	0.000702	0.0372	CcSEcCtD
Afatinib—ERBB4—Adaptive Immune System—HLA-DRB1—Graves' disease	0.000699	0.00118	CbGpPWpGaD
Afatinib—ERBB2—Immune System—CD40—Graves' disease	0.000697	0.00118	CbGpPWpGaD
Afatinib—IRAK1—Cytokine Signaling in Immune system—IFNG—Graves' disease	0.000696	0.00117	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—HLA-E—Graves' disease	0.000693	0.00117	CbGpPWpGaD
Afatinib—ERBB2—Immune System—CTLA4—Graves' disease	0.000687	0.00116	CbGpPWpGaD
Afatinib—ERBB4—Immune System—CD40—Graves' disease	0.000687	0.00116	CbGpPWpGaD
Afatinib—ERBB2—Adaptive Immune System—ICAM1—Graves' disease	0.000681	0.00115	CbGpPWpGaD
Afatinib—LCK—Cytokine Signaling in Immune system—IL2RA—Graves' disease	0.000679	0.00115	CbGpPWpGaD
Afatinib—ERBB4—Immune System—CTLA4—Graves' disease	0.000677	0.00114	CbGpPWpGaD
Afatinib—BLK—Immune System—HLA-E—Graves' disease	0.000676	0.00114	CbGpPWpGaD
Afatinib—Pruritus—Propylthiouracil—Graves' disease	0.000674	0.0357	CcSEcCtD
Afatinib—BLK—Adaptive Immune System—HLA-DRB1—Graves' disease	0.000672	0.00113	CbGpPWpGaD
Afatinib—LCK—Cytokine Signaling in Immune system—HLA-A—Graves' disease	0.000672	0.00113	CbGpPWpGaD
Afatinib—ERBB4—Adaptive Immune System—ICAM1—Graves' disease	0.000671	0.00113	CbGpPWpGaD
Afatinib—Nausea—Methimazole—Graves' disease	0.000666	0.0352	CcSEcCtD
Afatinib—BLK—Immune System—CD40—Graves' disease	0.000661	0.00112	CbGpPWpGaD
Afatinib—IRAK1—Immune System—IFIH1—Graves' disease	0.000655	0.00111	CbGpPWpGaD
Afatinib—BLK—Immune System—CTLA4—Graves' disease	0.000651	0.0011	CbGpPWpGaD
Afatinib—ABCB1—Allograft Rejection—IFNG—Graves' disease	0.000646	0.00109	CbGpPWpGaD
Afatinib—BLK—Adaptive Immune System—ICAM1—Graves' disease	0.000645	0.00109	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—HLA-B—Graves' disease	0.000631	0.00107	CbGpPWpGaD
Afatinib—EGFR—MAPK Signaling Pathway—IL1B—Graves' disease	0.000624	0.00105	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—TSHR—Graves' disease	0.000623	0.00105	CbGpPWpGaD
Afatinib—IRAK1—Cytokine Signaling in Immune system—IL1B—Graves' disease	0.00062	0.00105	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—TSHR—Graves' disease	0.000614	0.00104	CbGpPWpGaD
Afatinib—LCK—Cytokine Signaling in Immune system—HLA-DRB1—Graves' disease	0.000614	0.00104	CbGpPWpGaD
Afatinib—Vomiting—Propylthiouracil—Graves' disease	0.000606	0.0321	CcSEcCtD
Afatinib—EGFR—Spinal Cord Injury—TNF—Graves' disease	0.000601	0.00101	CbGpPWpGaD
Afatinib—Rash—Propylthiouracil—Graves' disease	0.000601	0.0318	CcSEcCtD
Afatinib—Dermatitis—Propylthiouracil—Graves' disease	0.0006	0.0318	CcSEcCtD
Afatinib—Headache—Propylthiouracil—Graves' disease	0.000597	0.0316	CcSEcCtD
Afatinib—EGFR—Innate Immune System—HLA-E—Graves' disease	0.000592	0.000999	CbGpPWpGaD
Afatinib—LCK—Cytokine Signaling in Immune system—ICAM1—Graves' disease	0.000589	0.000994	CbGpPWpGaD
Afatinib—ABCB1—Allograft Rejection—IL1B—Graves' disease	0.000576	0.000973	CbGpPWpGaD
Afatinib—ABCB1—Transmembrane transport of small molecules—GABRA3—Graves' disease	0.000575	0.000971	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—HLA-E—Graves' disease	0.000571	0.000963	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—HLA-E—Graves' disease	0.000569	0.00096	CbGpPWpGaD
Afatinib—Nausea—Propylthiouracil—Graves' disease	0.000566	0.03	CcSEcCtD
Afatinib—ERBB2—Immune System—HLA-DQB1—Graves' disease	0.000566	0.000955	CbGpPWpGaD
Afatinib—PHKG2—Disease—CD4—Graves' disease	0.000565	0.000954	CbGpPWpGaD
Afatinib—ERBB4—Immune System—HLA-DQB1—Graves' disease	0.000557	0.000941	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—CD40—Graves' disease	0.000556	0.000938	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—HLA-E—Graves' disease	0.000548	0.000925	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—CTLA4—Graves' disease	0.000548	0.000925	CbGpPWpGaD
Afatinib—BLK—Immune System—HLA-DQB1—Graves' disease	0.000536	0.000905	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—GC—Graves' disease	0.000536	0.000905	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—CD40—Graves' disease	0.000536	0.000904	CbGpPWpGaD
Afatinib—EPHA6—Developmental Biology—TNF—Graves' disease	0.000534	0.000902	CbGpPWpGaD
Afatinib—LCK—HIV Infection—CD4—Graves' disease	0.000533	0.000899	CbGpPWpGaD
Afatinib—ERBB2—Immune System—CD8A—Graves' disease	0.000528	0.000892	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—CTLA4—Graves' disease	0.000528	0.000891	CbGpPWpGaD
Afatinib—ERBB2—Innate Immune System—CD4—Graves' disease	0.000521	0.00088	CbGpPWpGaD
Afatinib—ERBB4—Immune System—CD8A—Graves' disease	0.00052	0.000879	CbGpPWpGaD
Afatinib—EGFR—Disease—B3GNT2—Graves' disease	0.000519	0.000877	CbGpPWpGaD
Afatinib—IRAK1—Immune System—HLA-E—Graves' disease	0.000516	0.000871	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—IL2RA—Graves' disease	0.000514	0.000867	CbGpPWpGaD
Afatinib—ERBB4—Innate Immune System—CD4—Graves' disease	0.000513	0.000866	CbGpPWpGaD
Afatinib—ABL1—Immune System—IFIH1—Graves' disease	0.000513	0.000866	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—TSHR—Graves' disease	0.00051	0.000861	CbGpPWpGaD
Afatinib—ERBB2—Immune System—HLA-B—Graves' disease	0.000508	0.000858	CbGpPWpGaD
Afatinib—IRAK1—Immune System—CD40—Graves' disease	0.000504	0.000851	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—FASLG—Graves' disease	0.000504	0.000851	CbGpPWpGaD
Afatinib—BLK—Immune System—CD8A—Graves' disease	0.000501	0.000845	CbGpPWpGaD
Afatinib—ERBB4—Immune System—HLA-B—Graves' disease	0.000501	0.000845	CbGpPWpGaD
Afatinib—LCK—Disease—B3GNT2—Graves' disease	0.000501	0.000845	CbGpPWpGaD
Afatinib—ERBB2—Adaptive Immune System—CD4—Graves' disease	0.0005	0.000845	CbGpPWpGaD
Afatinib—IRAK1—Immune System—CTLA4—Graves' disease	0.000497	0.000839	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—HLA-B—Graves' disease	0.000494	0.000833	CbGpPWpGaD
Afatinib—ERBB4—Adaptive Immune System—CD4—Graves' disease	0.000493	0.000832	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—Graves' disease	0.000486	0.00082	CbGpPWpGaD
Afatinib—BLK—Immune System—HLA-B—Graves' disease	0.000482	0.000813	CbGpPWpGaD
Afatinib—ABL1—Integrated Pancreatic Cancer Pathway—TNF—Graves' disease	0.000478	0.000808	CbGpPWpGaD
Afatinib—ERBB2—Immune System—IL2RA—Graves' disease	0.000476	0.000804	CbGpPWpGaD
Afatinib—BLK—Adaptive Immune System—CD4—Graves' disease	0.000474	0.0008	CbGpPWpGaD
Afatinib—ERBB2—Immune System—HLA-A—Graves' disease	0.000471	0.000795	CbGpPWpGaD
Afatinib—ERBB4—Immune System—IL2RA—Graves' disease	0.000469	0.000792	CbGpPWpGaD
Afatinib—ERBB4—Immune System—HLA-A—Graves' disease	0.000464	0.000783	CbGpPWpGaD
Afatinib—EGFR—MAPK Signaling Pathway—TNF—Graves' disease	0.000453	0.000765	CbGpPWpGaD
Afatinib—BLK—Immune System—IL2RA—Graves' disease	0.000451	0.000762	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—HLA-DQB1—Graves' disease	0.000451	0.000761	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—TSHR—Graves' disease	0.000451	0.000761	CbGpPWpGaD
Afatinib—LCK—Cytokine Signaling in Immune system—IFNG—Graves' disease	0.000448	0.000757	CbGpPWpGaD
Afatinib—BLK—Immune System—HLA-A—Graves' disease	0.000446	0.000753	CbGpPWpGaD
Afatinib—EGFR—Immune System—IFIH1—Graves' disease	0.000438	0.00074	CbGpPWpGaD
Afatinib—ERBB2—Disease—HLA-A—Graves' disease	0.000435	0.000734	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—HLA-DQB1—Graves' disease	0.000435	0.000734	CbGpPWpGaD
Afatinib—ERBB2—Immune System—HLA-DRB1—Graves' disease	0.00043	0.000726	CbGpPWpGaD
Afatinib—ERBB4—Disease—HLA-A—Graves' disease	0.000428	0.000723	CbGpPWpGaD
Afatinib—ERBB4—Immune System—HLA-DRB1—Graves' disease	0.000424	0.000715	CbGpPWpGaD
Afatinib—LCK—Hemostasis—IL2RA—Graves' disease	0.000423	0.000714	CbGpPWpGaD
Afatinib—LCK—Immune System—IFIH1—Graves' disease	0.000422	0.000713	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—HLA-B—Graves' disease	0.000422	0.000712	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—CD8A—Graves' disease	0.000421	0.000711	CbGpPWpGaD
Afatinib—ABCB1—Allograft Rejection—TNF—Graves' disease	0.000418	0.000706	CbGpPWpGaD
Afatinib—ERBB2—Immune System—ICAM1—Graves' disease	0.000413	0.000697	CbGpPWpGaD
Afatinib—IRAK1—Immune System—HLA-DQB1—Graves' disease	0.000409	0.000691	CbGpPWpGaD
Afatinib—EGFR—Integrated Pancreatic Cancer Pathway—TNF—Graves' disease	0.000409	0.00069	CbGpPWpGaD
Afatinib—BLK—Immune System—HLA-DRB1—Graves' disease	0.000408	0.000688	CbGpPWpGaD
Afatinib—ERBB4—Immune System—ICAM1—Graves' disease	0.000407	0.000687	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—HLA-B—Graves' disease	0.000407	0.000686	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—B3GNT2—Graves' disease	0.000406	0.000686	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—CD8A—Graves' disease	0.000406	0.000685	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—HLA-B—Graves' disease	0.000405	0.000684	CbGpPWpGaD
Afatinib—ABL1—Immune System—HLA-E—Graves' disease	0.000404	0.000681	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—CXCL10—Graves' disease	0.000403	0.00068	CbGpPWpGaD
Afatinib—LCK—Cytokine Signaling in Immune system—IL1B—Graves' disease	0.0004	0.000675	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—CXCL10—Graves' disease	0.000397	0.00067	CbGpPWpGaD
Afatinib—ERBB2—Developmental Biology—TNF—Graves' disease	0.000395	0.000667	CbGpPWpGaD
Afatinib—ABL1—Immune System—CD40—Graves' disease	0.000394	0.000666	CbGpPWpGaD
Afatinib—BLK—Immune System—ICAM1—Graves' disease	0.000391	0.000661	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—HLA-B—Graves' disease	0.00039	0.000659	CbGpPWpGaD
Afatinib—ABL1—Immune System—CTLA4—Graves' disease	0.000389	0.000656	CbGpPWpGaD
Afatinib—IRAK1—Immune System—CD8A—Graves' disease	0.000382	0.000645	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—CD4—Graves' disease	0.000377	0.000636	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—HLA-A—Graves' disease	0.000375	0.000634	CbGpPWpGaD
Afatinib—IRAK1—Immune System—HLA-B—Graves' disease	0.000367	0.00062	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—HLA-A—Graves' disease	0.000362	0.000611	CbGpPWpGaD
Afatinib—EGFR—Immune System—HLA-E—Graves' disease	0.000345	0.000582	CbGpPWpGaD
Afatinib—IRAK1—Immune System—IL2RA—Graves' disease	0.000344	0.000581	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—HLA-DRB1—Graves' disease	0.000343	0.000579	CbGpPWpGaD
Afatinib—IRAK1—Immune System—HLA-A—Graves' disease	0.00034	0.000575	CbGpPWpGaD
Afatinib—EGFR—Immune System—CD40—Graves' disease	0.000337	0.000569	CbGpPWpGaD
Afatinib—LCK—Immune System—HLA-E—Graves' disease	0.000332	0.000561	CbGpPWpGaD
Afatinib—EGFR—Immune System—CTLA4—Graves' disease	0.000332	0.000561	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—HLA-DRB1—Graves' disease	0.00033	0.000558	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—CXCL10—Graves' disease	0.00033	0.000557	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—ICAM1—Graves' disease	0.000329	0.000556	CbGpPWpGaD
Afatinib—LCK—Immune System—CD40—Graves' disease	0.000325	0.000548	CbGpPWpGaD
Afatinib—ABL1—Immune System—HLA-DQB1—Graves' disease	0.00032	0.00054	CbGpPWpGaD
Afatinib—LCK—Immune System—CTLA4—Graves' disease	0.00032	0.00054	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—ICAM1—Graves' disease	0.000317	0.000535	CbGpPWpGaD
Afatinib—ERBB2—Immune System—IFNG—Graves' disease	0.000314	0.00053	CbGpPWpGaD
Afatinib—IRAK1—Immune System—HLA-DRB1—Graves' disease	0.000311	0.000525	CbGpPWpGaD
Afatinib—ERBB4—Immune System—IFNG—Graves' disease	0.00031	0.000522	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—IL2RA—Graves' disease	0.000308	0.00052	CbGpPWpGaD
Afatinib—ERBB2—Immune System—CD4—Graves' disease	0.000303	0.000512	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—IL2RA—Graves' disease	0.000303	0.000512	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—TSHR—Graves' disease	0.000301	0.000509	CbGpPWpGaD
Afatinib—ABL1—Immune System—CD8A—Graves' disease	0.000299	0.000505	CbGpPWpGaD
Afatinib—ERBB4—Immune System—CD4—Graves' disease	0.000299	0.000505	CbGpPWpGaD
Afatinib—IRAK1—Immune System—ICAM1—Graves' disease	0.000299	0.000504	CbGpPWpGaD
Afatinib—BLK—Immune System—IFNG—Graves' disease	0.000298	0.000503	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—CD4—Graves' disease	0.000295	0.000498	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CXCL10—Graves' disease	0.000291	0.000492	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—TSHR—Graves' disease	0.00029	0.00049	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—GC—Graves' disease	0.00029	0.000489	CbGpPWpGaD
Afatinib—BLK—Immune System—CD4—Graves' disease	0.000288	0.000485	CbGpPWpGaD
Afatinib—ABL1—Immune System—HLA-B—Graves' disease	0.000288	0.000485	CbGpPWpGaD
Afatinib—ERBB2—Immune System—IL1B—Graves' disease	0.00028	0.000473	CbGpPWpGaD
Afatinib—ERBB2—Disease—CD4—Graves' disease	0.00028	0.000473	CbGpPWpGaD
Afatinib—ERBB4—Immune System—IL1B—Graves' disease	0.000276	0.000466	CbGpPWpGaD
Afatinib—ERBB4—Disease—CD4—Graves' disease	0.000276	0.000466	CbGpPWpGaD
Afatinib—EGFR—Immune System—HLA-DQB1—Graves' disease	0.000274	0.000462	CbGpPWpGaD
Afatinib—ABL1—Immune System—IL2RA—Graves' disease	0.000269	0.000455	CbGpPWpGaD
Afatinib—ABL1—Immune System—HLA-A—Graves' disease	0.000266	0.00045	CbGpPWpGaD
Afatinib—BLK—Immune System—IL1B—Graves' disease	0.000266	0.000448	CbGpPWpGaD
Afatinib—LCK—Immune System—HLA-DQB1—Graves' disease	0.000264	0.000445	CbGpPWpGaD
Afatinib—EGFR—Immune System—CD8A—Graves' disease	0.000255	0.000431	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—IL2RA—Graves' disease	0.000252	0.000425	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—CD4—Graves' disease	0.000252	0.000425	CbGpPWpGaD
Afatinib—LCK—Immune System—CD8A—Graves' disease	0.000246	0.000416	CbGpPWpGaD
Afatinib—EGFR—Immune System—HLA-B—Graves' disease	0.000246	0.000415	CbGpPWpGaD
Afatinib—ABL1—Immune System—HLA-DRB1—Graves' disease	0.000243	0.000411	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—CD4—Graves' disease	0.000243	0.00041	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—CD4—Graves' disease	0.000242	0.000408	CbGpPWpGaD
Afatinib—LCK—Immune System—HLA-B—Graves' disease	0.000237	0.0004	CbGpPWpGaD
Afatinib—ABL1—Immune System—ICAM1—Graves' disease	0.000234	0.000394	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—CD4—Graves' disease	0.000233	0.000393	CbGpPWpGaD
Afatinib—EGFR—Immune System—IL2RA—Graves' disease	0.00023	0.000389	CbGpPWpGaD
Afatinib—EGFR—Immune System—HLA-A—Graves' disease	0.000228	0.000384	CbGpPWpGaD
Afatinib—IRAK1—Immune System—IFNG—Graves' disease	0.000227	0.000384	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—TNF—Graves' disease	0.000224	0.000378	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—IL2RA—Graves' disease	0.000223	0.000376	CbGpPWpGaD
Afatinib—LCK—Immune System—IL2RA—Graves' disease	0.000222	0.000375	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—B3GNT2—Graves' disease	0.00022	0.000371	CbGpPWpGaD
Afatinib—IRAK1—Immune System—CD4—Graves' disease	0.000219	0.00037	CbGpPWpGaD
Afatinib—LCK—Immune System—HLA-A—Graves' disease	0.000219	0.00037	CbGpPWpGaD
Afatinib—EGFR—Disease—HLA-A—Graves' disease	0.00021	0.000355	CbGpPWpGaD
Afatinib—EGFR—Immune System—HLA-DRB1—Graves' disease	0.000208	0.000351	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—Graves' disease	0.000206	0.000348	CbGpPWpGaD
Afatinib—IRAK1—Immune System—IL1B—Graves' disease	0.000203	0.000342	CbGpPWpGaD
Afatinib—LCK—Disease—HLA-A—Graves' disease	0.000203	0.000342	CbGpPWpGaD
Afatinib—LCK—Immune System—HLA-DRB1—Graves' disease	0.0002	0.000338	CbGpPWpGaD
Afatinib—EGFR—Immune System—ICAM1—Graves' disease	0.0002	0.000337	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CXCL10—Graves' disease	0.000195	0.000329	CbGpPWpGaD
Afatinib—LCK—Immune System—ICAM1—Graves' disease	0.000192	0.000325	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—TNF—Graves' disease	0.000191	0.000323	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CXCL10—Graves' disease	0.000188	0.000317	CbGpPWpGaD
Afatinib—ABL1—Immune System—IFNG—Graves' disease	0.000178	0.0003	CbGpPWpGaD
Afatinib—ABL1—Immune System—CD4—Graves' disease	0.000172	0.00029	CbGpPWpGaD
Afatinib—ABL1—Immune System—IL1B—Graves' disease	0.000159	0.000268	CbGpPWpGaD
Afatinib—EGFR—Immune System—IFNG—Graves' disease	0.000152	0.000256	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IL2RA—Graves' disease	0.000149	0.000251	CbGpPWpGaD
Afatinib—EGFR—Immune System—CD4—Graves' disease	0.000147	0.000248	CbGpPWpGaD
Afatinib—LCK—Immune System—IFNG—Graves' disease	0.000146	0.000247	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IL2RA—Graves' disease	0.000143	0.000242	CbGpPWpGaD
Afatinib—LCK—Immune System—CD4—Graves' disease	0.000141	0.000239	CbGpPWpGaD
Afatinib—EGFR—Immune System—IL1B—Graves' disease	0.000135	0.000229	CbGpPWpGaD
Afatinib—EGFR—Disease—CD4—Graves' disease	0.000135	0.000229	CbGpPWpGaD
Afatinib—LCK—Immune System—IL1B—Graves' disease	0.000131	0.00022	CbGpPWpGaD
Afatinib—LCK—Disease—CD4—Graves' disease	0.000131	0.00022	CbGpPWpGaD
